C12N 2760/16052
Relating to complementing cells and packaging systems for producing virus or viral
Official title: relating to complementing cells and packaging systems for producing virus or viral particles
C12N2760/16052 (Relating to complementing cells and packaging systems for producing virus or viral) appears on 15 US grants and 26 published applications in this corpus.
Search patents in C12N- Granted patents
- 15
- Published applications
- 26
- Assignees
- 19
- Inventors
- 37
- Latest grant
- 6 Aug 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 3 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 3 | 0 |
| 2016 | 0 | 4 |
| 2017 | 0 | 0 |
| 2018 | 1 | 3 |
| 2019 | 1 | 3 |
| 2020 | 3 | 1 |
| 2021 | 2 | 1 |
| 2022 | 1 | 2 |
| 2023 | 1 | 0 |
| 2024 | 2 | 3 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Production of viruses in cell culture6 Aug 2024US 12,054,750 B2Commonwealth Scientific and Industrial Research Organisation
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof16 Jul 2024US 12,037,364 B2Sanofi Pasteur Limited
- Virus-like particles co-expressing Toxoplasma gondii IMC, ROP18, and MIC8, and pharmaceutical composition comprising the same3 Jan 2023US 11,542,477 B2Health Park Incorporated
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof10 May 2022US 11,325,947 B2Sanofi Pasteur Limited
- Production of viruses in cell culture16 Nov 2021US 11,174,466 B2Commonwealth Scientific and Industrial Research Organisation
- Production of viruses in cell culture9 Jan 2025US 2025/0011731 A1Commonwealth Scientific and Industrial Research Organisation
- A vaccine for coronavirus and influenza virus, and method for preparation thereof5 Dec 2024US 2024/0398930 A1Bharat Biotech International Limited
- Vaccine compositions and methods of use thereof16 May 2024US 2024/0156948 A1Excepgen Inc.
- Making influenza virus vaccines without using eggs15 Feb 2024US 2024/0050553 A1Seqirus UK Limited
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof4 Aug 2022US 2022/0242918 A1Sanofi Pasteur Limited
Most cited
By later US patents
- High titer recombinant influenza viruses with enhanced replication in vero cells26US 9,109,013 B2Wisconsin Alumni Research Foundation · 2015
- High titer recombinant influenza viruses with enhanced replication in vero cells23US 10,059,925 B2Wisconsin Alumni Research Foundation (WARF) · 2018
- High titer recombinant influenza viruses with enhanced replication in vero cells17US 10,808,229 B2Wisconsin Alumni Research Foundation (WARF) · 2020
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof2US 10,584,148 B2Sanofi Pasteur Limited · 2020
- Engineered influenza antigenic polypeptides and immunogenic compositions thereof2US 11,325,947 B2Sanofi Pasteur Limited · 2022